Viz.ai, Inc. the leading applied artificial intelligence healthcare company, is excited to announce the expansion of Viz RECRUIT, Viz’s Clinical Trial Platform at the International Stroke Conference in Los Angeles (Feb. 19-21). Viz RECRUIT employs artificial intelligence (AI) to automatically identify potential patients for clinical trials and is currently being utilized in the AI ENRICH study to speed up enrollment and increase randomization of patient population.
Viz RECRUIT, in use for the AI ENRICH study, will now support automatic detection of a broader set of cerebrovascular diseases including:
Intracerebral Hemorrhage (ICH) Detection and Volume Quantification. Now being used in the AI ENRICH study, these algorithms detect the presence of an ICH and automatically quantify ICH volumes.
Automatic Quantification of Ischemic Core. Automatically calculates ASPECTS and the volume of an acute ischemic brain which has already infarcted or is irrevocably destined to infarct regardless of reperfusion.
Aneurysm Detection. Automatically detects and quantifies aneurysms on CT angiogram.
Viz RECRUIT continues to support patient enrollment and clinical management with expanded functionality including:
- Patient Qualification. Notifies the Site principal Investigator when a patient has met specific imaging criteria and may be eligible for trial enrollment.
- Image Sharing. Images can be shared with investigators or the core lab at the touch of a button.
- Real Time Collaboration. Investigators can communicate about potential trial patients in real time, discussing patient eligibility, surgical approach and post op management.
- Trial Analytics. An administrative dashboard providing data and intelligence to principal investigators and industry sponsors on trial sites and patient populations.
- Disease Location Identification and Quantification. “Under the hood” disease location showing what the AI algorithm “sees” (e.g. for LVOs, aneurysms).
“Viz.ai continues to support the research community by bringing cutting edge technology into healthcare. The addition of new algorithms and trial workflow capabilities to its groundbreaking Viz RECRUIT platform has the potential to revolutionize how we run clinical trials,” said Dr. Chris Kellner, Assistant Professor and Director of Intracerebral Hemorrhage Program at Mount Sinai Health System and the National Principal Investigator for the MIRROR, INSIGHT, VITAL, and VIGOR studies. “Viz RECRUIT allows research teams to identify more patients and see what is going on in our trials in real time.”
Clinical Trial enrollment is one of the key risk factors in running clinical trials. In one case, a report indicated that 20 percent of cancer clinical trials fail because of inadequate patient recruitment. Another 2011 report from the Tufts Center for the Study of Drug Development 2011 report found that two thirds of clinical trial sites don’t meet enrollment requirements for individual trials. In a study which analyzed 787 phase 2 and phase 3 adult clinical cancer trials that launched between 2000-2011. The team found that 18% of the NCTN trials either closed due to insufficient participants, or they were recruiting participants at less than half of the target rate 3 or more years after they launched.
“We are delighted to work with some of the world’s top investigators to help them in their patient recruitment and support health care industry sponsors in clinical trial management,” said Chris Mansi, CEO of Viz.ai. “We aim to accelerate the cutting-edge research our partners are doing.”
About Viz.ai, Inc.
Viz.ai is the leader in applied artificial intelligence in healthcare. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about suspected stroke patients straight to a specialist who can intervene and treat.
In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis.
Viz.ai is located in San Francisco and Tel Aviv.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005523/en/